The amount of amyloid ß (Aß) in the brains of people with mild cognitive impairment (MCI) is contributing to early memory loss, and increases with severity of symptoms, finds a study in BioMed Central’s open access journal Alzheimer’s Research & Therapy. The non-invasive study which used 18F-florbetaben to find Aß plaques in brain scans to also show that in MCI the affect of Aß on memory loss is independent of other aspects of mental decline.
